Cargando…
NP-114: Lesson Learned: Management of patients with Multiple Myeloma (MM) and their response to two doses of COVID-19 RNA vaccine
INTRODUCTION: COVID-19 has resulted in a global, social and economic disruptions, especially a widespread shortage in supplied and stress on the healthcare system. The global effort to develop an effective vaccine was monumental. The COVID-19 mRNA vaccine is effective in preventing morbidity and mor...
Autores principales: | Verina, Daniel, Van Oekelen, Oliver, Gleason, Charles, Agte, Sarita, Srivastava, Komal, Beach, Katherine, Aleman, Adolfo, Mouhieddine, Tarek, Chari, Ajai, Cordon-Cardo, Carlos, Krammer, Florian, Jagannath, Sundar, Simon, Viviana, Wajnberg, Ania, Parekh, Samir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580179/ http://dx.doi.org/10.1016/S2152-2650(21)02367-3 |
Ejemplares similares
-
OAB-048: Suboptimal humoral immune response to SARS-CoV-2 mRNA vaccination in myeloma patients is associated with anti-CD38 mAb and BCMA-targeted treatment
por: Oekelen, Oliver Van, et al.
Publicado: (2021) -
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma
por: Van Oekelen, Oliver, et al.
Publicado: (2021) -
Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment
por: Van Oekelen, Oliver, et al.
Publicado: (2021) -
Cellular Immune Composition in Multiple Myeloma Patients Associated with Variable Humoral Responses to Sars-Cov-2 Vaccination
por: Kogan Zajdman, Ariel, et al.
Publicado: (2022) -
Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients
por: Aleman, Adolfo, et al.
Publicado: (2022)